Skip to content

Effects of Non-invasive Brain Stimulation on Pain Avoidance Behavior in Chronic Pain Patients

Alpha tACS and Pain Avoidance Behavior in Chronic Pain Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07791966
Enrollment
30
Registered
2026-08-28
Start date
2026-10-01
Completion date
2028-12-01
Last updated
2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndrome (CRPS)

Brief summary

Pain avoidance helps with survival. However, chronic pain patients often avoid valued life activities fearing onset or exacerbation of pain. Hence, pain avoidance no longer protects, but reduces quality of life. The goal of this clinical trial is to learn if non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) impact pain avoidance behavior in chronic pain patients. tACS is a way to gently stimulate the brain using a small, portable device. It sends an extremely weak, continuous alternating current through the scalp. Participants will either get real tACS or a fake (sham) version. Real tACS will stimulate the brain in the alpha frequency (8-12 Hz) which has been found to influence pain avoidance behavior, whereas sham tACS will stimulate the brain in a different frequency that is not known to influence avoidance behavior. The main questions it aims to answer are: Does tACS alter the way chronic pain patients confront pain in terms of avoidance behavior? How does tACS impact brain signals related to pain avoidance behavior? Participants will: 1. fill out self-administered questionnaires asking about their medication use, personality and temperament, mood, including anxiety and depression, current pain level, and any disability you have due to your pain. 2. perform of a pain avoidance task before, during and after 'real' tACS or 'sham' tACS. They may also be asked to stay quiet before, during and after tACS. During this period, we will scan the brain using a neuroimaging device called Magnetoencephalography (MEG). Additionally, Electroencephalography (EEG) brain signals will also be collected using electrodes affixed to the scalp. We may also measure Skin conductance response (SCR) and electrocardiography (EKG) using electrodes affixed to the skin. 3. also get a T1 MRI if they do not have an implanted SCS, DRG, intrathecal pump, or other similar device that are not MRI compatible.

Interventions

DEVICEtranscranial alternating current stimulation (tACS)

Real tACS will stimulate the brain in the individual alpha frequency (8-12 Hz) measured from baseline MEG

Sponsors

The Cleveland Clinic
Lead SponsorOTHER
National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Diagnosed with Complex Regional Pain Syndrome (CRPS) Type I or II, based on Budapest criteria * 6 months or more of medically refractory severe pain * Average daily pain for past 30 days \>= 5 on 0-10 scale * Presence of allodynia and/or hyperalgesia * Lower extremity CRPS: bilateral or unilateral pain * Not concurrently treated with neurostimulation therapies such as spinal cord stimulators (SCS) * Absence of co-occurring severe psychiatric disorders (PHQ-9\<19 and/or GAD-7\<14)

Exclusion criteria

* Age under 18 years, pregnant women of any age * Any co-occurring pain diagnosis that might confound with allodynia/hyperalgesia resulting from CRPS reflecting a malfunction in sensory processing within the CNS. * Less than six months of medically refractory pain * Average daily pain for past 30 days \<5 on 0-10 scale * Absence of allodynia and/or hyperalgesia * Concurrent neurostimulation therapies such as SCS * Severe disorders or conditions (e.g., cardiovascular, liver issues), terminal illness * PHQ-9\>19 and/or GAD-7\>14 (severe depression/anxiety)

Design outcomes

Primary

MeasureTime frameDescription
magnitude of alpha frequency band powerPeriproceduralmeasured using MEG/EEG from resting-state and during the performance of pain avoidance task. The MEG/EEG neural signals will be transformed to frequency domain to measure the magnitude of power in the alpha band.

Secondary

MeasureTime frameDescription
standard deviation in R-R lengthPeriproceduralstandard deviation in R-R length (SDNN), a measure of heart rate variability from RR interval tachogram derived from EKG.
number of spontaneous skin conductance fluctuationsPeriproceduralnumber of spontaneous skin conductance fluctuations will be measured from galvanic skin conductance response time-series data.

Countries

United States

Contacts

CONTACTRaghavan Gopalakrishnan
gopalar@ccf.org2164459322

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026